Safety and Efficacy of Modified FOLFOX6 plus High-Dose Bevacizumab in Second-Line or Later Treatment of Patients with Metastatic Colorectal Cancer

Publisher： Karger

E-ISSN： 1421-9794|59|2|79-84

ISSN： 0009-3157

Source： Chemotherapy, Vol.59, Iss.2, 2013-07, pp. : 79-84

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and Efficacy of Modified FOLFOX6 for Treatment of Metastatic or Locally Advanced Colorectal Cancer

By  

Chemotherapy, Vol. 54, Iss. 5, 2008-09 ,pp. : 395-403

Karger

Access to resources Recommend Favorite

Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment

By  

Chemotherapy, Vol. 62, Iss. 1, 2016-09 ,pp. : 80-84

Karger

Access to resources Recommend Favorite

A Retrospective Study of the Safety and Efficacy of a First-Line Treatment with Modified FOLFOX-4 in Unresectable Advanced or Recurrent Gastric Cancer Patients

By  

Chemotherapy, Vol. 58, Iss. 5, 2013-01 ,pp. : 411-418

Karger

Access to resources Recommend Favorite

Modified FOLFOX6 Chemotherapy in Patients with Metastatic Urachal Cancer

By  

Chemotherapy, Vol. 59, Iss. 6, 2014-06 ,pp. : 402-406

Karger

Access to resources Recommend Favorite

Molecular Imaging Suggests Efficacy of Bevacizumab beyond the Second Line in Advanced Colorectal Cancer Patients

By  

Chemotherapy, Vol. 54, Iss. 6, 2008-09 ,pp. : 421-424

Karger

Access to resources Recommend Favorite